Discovery

Development

Testing

Clinical Manufacture

Commercial Manufacture

Drug Product Fill & Finish

Antibody Drug Conjugates

Technologies & Platforms

WuXi Biologic’s biosafety testing facility, located in Suzhou, China occupies over 38,000 sq. ft. of lab space. Our high-quality services include:

As the first non-state affiliated lab of its type in China and Asia,  WuXi Biologics is one of the rare CDMOs that offer in-house biosafety testing capabilities.  These capabilities allow WuXi to reduce our clients drug development timelines because we eliminate the problematic hand-offs inherent in the historic multiple vendor model.

Integrated – Expertise – Quality – Capacity
See the benefits of WuXi’s truly ONE services

 

Viral Clearance/Inactivation

WuXi Biologics offers custom studies to validate removal and inactivation, of viruses from product purification processes. Combined with our U.S. affiliates, we are the clear leader in this field with more than two decades of experience. Our scientific and quality teams have comprehensive expertise in process development, use of infectivity and quantitative PCR virus detection and titer assays and international regulatory considerations for early- and late-stage products.

Extensive Experience

Our experience spans a broad number of different inactivation or removal unit operations/processes including:
– Heat / Pasteurization
– Column
– Low and High pH
– Chromatography
– Solvent / Detergent
– Filtration
– Irradiation
– Cleaning
– Sterilization
– Kinetics of Inactivation
– High-Energy Light
– Coupon Studies

High-purity, High-titer Virus Stocks

As preparation, purification and use of high-purity, high-titer viral stocks is one of the most critical aspects in the performance of a viral clearance study, we set the standard for how these stocks should be made, with refined and proprietary purification techniques. Our ultra-purified stocks help ensure the data generated is the most accurate assessment of your processes’ ability to clear or inactivate virus.

Real-time Quantitative PCR / Large-volume Virus Plaque Assay

For processes in which both clearance/removal and inactivation occur, qPCR has become a leading technology in determining clearance and removal, or to complement standard viral titration assays. we developed over 15 qPCR assays to common model viruses used in viral clearance studies.

Additionally, we have performed many large-volume studies, which have demonstrated that a higher-log reduction value can be realized for a given process step, in combination with the use of the virus plaque assay. The virus plaque assay allows for a higher claim of LRV, as well as proving to be a more precise method for detection of infectious units for most viruses.

 

Cell Line Characterization (CLC)

Successful characterization of Master, Working and End-of-Production Cell Banks has many essential elements, including identity and detection of micro-organisms and mycoplasma. The most highly customized element is the detection of adventitious virus. WuXi Biologics along with its U.S.-based WuXi AppTec affiliate is the clear leader in this field, with exceptional expertise and over 25 years of experience.

Dedicated virology, molecular biology, cell biology, in-life and microbiology labs provide high-quality and comprehensive CLC services that meet ICH and CFDA guidelines for a wide variety of cell line types.  Assessment includes:

  • Sterility Testing
  • Mycoplasma Detection
  • Cell LIne Identity
  • Cell Morphology and Growth Characteristics
  • Adventitious Virus Detection via in vitro, in vivo & qPCR methodologies
  • Testing for Bovine or Porcine Viruses (9CFR requirement)

 

Unprocessed Bulk Lot Release

Cell harvest material/unprocessed bulk must be tested for the presence of adventious virus and mycoplasma.  WuXi Biologics offers in vitro and molecular biology (qPCR) approaches under GLP and GMP standards for detection of these micro-organisms.

BACK